City Rounds

City Rounds is a unique educational initiative designed to provide up and coming rheumatologists a chance to interact with leaders in RA treatment in a round-table format.

The round-table discussion will be enhanced by educational resources designed to reinforce key learning take-aways you can use in your clinical practice. Please join us for this unique and informative event.

To register for one of our upcoming meetings, view the schedule below.

We look forward to seeing you at a meeting!


The goal of this program is to provide important clinical data on issues related to the management of RA.


This educational program is targeted at physicians and other healthcare providers who specialize in the management of patients with RA.


After completing this activity, the participants should be better able to:
• Develop an evidence-based treatment regimen using the latest clinical evidence
• Explain the disease and the treatment options to patients
• Recognize and communicate the risks and benefits of RA therapy
• Identify barriers to optimal management of patients with RA


This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of Purdue University College of Pharmacy and Focus Medical Communications. Purdue University College of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.


Purdue University College of Pharmacy designates this live activity for a maximum of
1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is supported by educational grants from AbbVie, Inc., Janssen-Biotech, Inc. Pfizer Inc., and Sanofi-aventis US.


All faculty AND staff involved in the planning, review or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.

All additional planning committee members, reviewers and Purdue University College of Pharmacy staff have no relationships to disclose.


Leonard H. Calabrese, DO

Dr. Calabrese has served as a consultant for AbbVie Inc., Aventis, Bristol-Myers Squibb, Crescendo, Genentech, GlaxoSmithKline and Janssen.

John J. Cush, MD

Dr. Cush has served as a consultant for AbbVie Inc., Amgen, Bristol-Myers Squibb, Celgene, Genentech, Janssen, Pfizer and UCB. He has also been a clinical investigator for Amgen, Celgene, CORRONA, Genentech, Novartis, Pfizer and UCB.

Arthur Kavanaugh, MD

Dr. Kavanaugh has received grants and/or research support from AbbVie Inc., Amgen, BMS, Celgene, Janssen, Novartis, Pfizer, UCB, and Roche.

Jonathan Kay, MD

Dr. Kay has received grants and research support, which was paid to the University of Massachusetts Medical School, from AbbVie Inc., Eli Lilly and Company, Pfizer Inc., Genentech Inc., Roche Laboratories, Inc., and UCB, Inc. He has been an advisor for Amgen, Inc., AbbVie Inc., AstraZeneca, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Crescendo Bioscience, Inc., Eli Lilly and Company, Epirus Biopharmaceuticals, Inc., Genentech Inc., GlaxoSmithKline PLC, Hospira, Inc., Janssen Biotech, Inc., Merck Sharp & Dohme Corp., Novartis Pharmaceuticals Corporation, Pfizer Inc., Samsung Bioepis, Sandoz Inc., Roche Laboratories, Inc. and UCB, Inc.

Nancy E. Lane, MD

Dr. Lane has received research support from Amgen, Alexion, Gilead Sciences Inc., and Pfizer. She has been a consultant or on a speaker bureau for Amgen, Novartis, and Regeneron. Dr. Lane has also been an advisor for Amgen and Regeneron. She has been on the Editorial Board for Seminars Arthritis and Rheumatism.

Eric Ruderman, MD

Dr. Ruderman has received grants and/or research support from AbbVie, Inc. and Pfizer. He has also been a consultant for Pfizer. Dr. Ruderman has been on an Advisory Board for AbbVie, Inc., Amgen, Celgene, Janssen, Lilly, Pfizer, UCB, Inc. and Vertex. He is on the Editorial Board of the Journal of Rheumatology and In Practice.

Sergio Schwartzman, MD

Dr. Schwartzman has been a consultant for or served on a Speakers Bureau for AbbVie Inc., Amgen, Genentech, Janssen, Pfizer, and UCB. He has also been an Advisory Board member for AbbVie Inc., Amgen, Genentech, Janssen, Pfizer, and UCB. Dr. Schwartzman has received honorarium from AbbVie Inc., Amgen, Genentech, Janssen, Pfizer, and UCB.